Background: Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of treatments for cancer. The company offers XYOTAX, a Phase III clinical trial chemotherapeutic agent, which links anti cancer agent called paclitaxel to a polyglutamate polymer for the treatment of non-small cell lung cancer and ovarian cancers in females. finance.yahoo.com/q/pr
Recent News:
DOR rejects buyout offer
April 12, 2007: DOR BioPharma said its board has rejected a buyout offer from Cell Therapeutics as being "inadequate for shareholders." biz.yahoo.com/bizj/070412/1446822.html
Cell Therapeutics cancer drug receives 'fast track' designation
April 11, 2007: Xyotax, a cancer drug made by Cell Therapeutics Inc., has a received "fast track" designation from the U.S. Food and Drug Administration for the treatment of certain types of cancer in women with a specific type of lung cancer. biz.yahoo.com/bizj/070411/1445306.html
$62.0 (04/13/07)
